Genmark Diagnostics Earnings: Your Sneak Peek to the Big Announcement
Genmark Diagnostics (NASDAQ:GNMK) will report earnings after markets close on Wednesday, May 8th. GenMark Diagnostics Inc. is a molecular diagnostics company focused on developing and commercializing its biomarker detection technology. The Company’s system supports a broad range of molecular diagnostic tests with a compact workstation and self-contained, disposable test cartridges.
Here is your Cheat Sheet to Genmark Diagnostics Earnings:
Earnings Expectations: Analysts expect earnings of $-0.17 per share on revenues of $9.56 million.
Analysts have a more negative outlook for the company’s next-quarter performance. Over the past three months, the average estimate for next quarter’s earnings has fallen from a loss of $0.13 to a loss $0.21. For the current year, the average estimate is a loss of $0.8, which is the same as the estimate ninety days ago.
Here’s how Genmark Diagnostics has been performing on an annual basis:
|Revenue ($) in millions||0.65||1.00||2.56||5.01||20.47|
|Diluted EPS ($)||-28.13||-4.41||-1.88||-1.45||-0.84|
Next, our CHEAT SHEET investing framework asks us to drill down to the recent quarterly data:
|Quarter||Dec. 31, 2011||Mar. 31, 2012||Jun. 30, 2012||Sep. 30, 2012||Dec. 31, 2012|
|Revenue ($) in millions||2.03||2.16||3.61||5.26||9.44|
|Diluted EPS ($)||-0.2703||-0.28||-0.26||-0.20||-0.1478|
Genmark Diagnostics has beat analyst estimates 3 times in the past four quarters. Shareholders could expect a boost if the company beats estimates.
“E = Earnings Are Increasing Quarter-Over-Quarter” is a core component of our successful CHEAT SHEET investing framework. Don’t waste another minute – click here to discover our CHEAT SHEET stock picks now!
(Company fundamentals provided by Xignite Financials. Email any earnings discrepancies to earnings [at] wallstcheatsheet.com)